Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2021 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 15, 2021 16:01 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an...
November 15, 2021 14:38 ET | Source: Eyenuk, Inc.

Eyenuk Announces Publication of Strong EyeArt® Pivotal Clinical Trial Results in JAMA Network Open

LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
November 15, 2021 08:45 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated...
November 15, 2021 07:30 ET | Source: Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021...
November 15, 2021 07:00 ET | Source: Oyster Point Pharma, Inc.

Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray

PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the...
November 15, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social...
November 15, 2021 01:00 ET | Source: Oxurion NV

OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)

THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 50% of the patient population suboptimally responding to anti-VEGF therapy Leuven, BE, Boston, MA, US – 15...
November 13, 2021 11:00 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned BLA submission with U.S. FDA in Q12022 ...
November 12, 2021 10:20 ET | Source: F. Hoffmann-La Roche Ltd

Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease

EU marketing authorisation follows approvals in Japan, the United Kingdom and AustraliaApproval based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to...